Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enavogliflozin - Daewoong

Next Previous
Drug Profile

Enavogliflozin - Daewoong

Alternative Names: Dapagliflozin; DWP-16001; DWP16001 drug A; DWP16001 drug B; DWP16001 drug C; Envlo; ODP 9401

Latest Information Update: 30 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antihypercalcaemics; Antihyperglycaemics; Benzofurans; Cyclopropanes; Heart failure therapies; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Heart failure

Most Recent Events

  • 23 Sep 2024 Daewoong Pharmaceutical plans a phase III trial in Diabetic nephropathies with moderate renal impairment(Treatment-experienced) in South Korea (PO) in September 2024 (NCT06606093)
  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 27 Nov 2023 Daewoong Pharmaceutical plans a phase III trial in Type 2 diabetes mellitus (In adults, In the elderly) (PO, Tablet) in December 2023 (NCT06141980)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top